{ "items": [ "\n\n
\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nResearch on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine \u2018AZD2816\u2019 in volunteers against the B.1.351 variant of concern \u2013 commonly known as the Beta variant.
\n \n\n\n \n 28 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers from the University of Oxford have today released their findings about the so-called \u2018correlates of protection\u2019 against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
\n \n\n\n \n 21 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nA new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
\n \n\n\n \n 17 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nRead about the topic in Samantha Vanderslott's latest publication.
\n \n\n\n \n 11 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n\n \n\n\n
\n \n\n \n \n \nAndrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.
\n \n\n\n \n 14 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nFor the one in ten who say they won\u2019t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.
\n \n\n\n \n 13 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nEver wondered what happens inside your cells when you are infected with a virus? Or wondered how the new COVID-19 vaccines work? The answer to both of these questions can be found in how our cells receive instructions to make proteins. Actually, our cells are a bit like factories...
\n \n\n\n \n 13 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nResearch, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.
\n \n\n\n \n 6 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nAndrew Pollard writes about vaccine equity in his article for The Conversation.
\n \n\n\n \n 6 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nDr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.
\n \n\n\n \n 29 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nCountries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance, and fewer restrictions and lockdowns, according to an article in The Lancet.
\n \n\n\n \n 14 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
\n \n\n\n \n 14 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nMedical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
\n \n\n\n \n 1 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nThe new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.
\n \n\n\n \n 25 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nOur partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
\n \n\n\n \n 22 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall. \r\nVaccine 100% effective against severe or critical symptomatic COVID-19. \r\nNo safety concerns reported
\n \n\n\n \n 19 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nSamantha Vanderslott, Andrew Pollard and Seilesh Kadambari discuss vaccine uptake among Black, Asian and minority ethnic communities in an article for The Conversation.
\n \n\n\n \n 4 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n\n \n\n\n
\n \n\n \n \n \nFour academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.
\n \n\n\n \n 24 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nThe first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
\n \n\n